Disorders of oxidised haemoglobin.

Methaemoglobinaemia arises from the production of non-functional haemoglobin containing oxidised Fe(3+) which results in reduced oxygen supply to the tissues and manifests as cyanosis in the patient. It can develop by three distinct mechanisms: genetic mutation resulting in the presence of abnormal haemoglobin, a deficiency of methaemoglobin reductase enzyme and toxin-induced oxidation of haemoglobin. The normal haemoglobin fold forms a pocket to bind the haem and stabilise its complex with molecular oxygen, simultaneously preventing spontaneous oxidation of the Fe(2+) ion chelated by the haem pyrroles and the globin histidines. In the abnormal, M forms of haemoglobin (Hb Ms) amino acid substitution in or near the haem pocket creates a propensity to form methaemoglobin instead of oxyhaemoglobin in the presence of molecular oxygen. Normally, haemoglobin continually oxidises but significant accumulation of methaemoglobin is prevented by the action of a group of methaemoglobin reductase enzymes. In the autosomal recessive form of methaemoglobinaemia there is a deficiency of one of these reductase enzymes thereby allowing accumulation of oxidised Fe(3+) in methaemoglobin. Oxidising drugs and other toxic chemicals may greatly enhance the normal spontaneous rate of methaemoglobin production and if levels exceed 70% of total haemoglobin, vascular collapse occurs resulting in coma and death. Under these conditions, if the source of toxicity can be eliminated methaemoglobin levels will return to normal. Disorders of oxidised haemoglobin are relatively easily diagnosed and in most cases, except for the presence of congenitally defective haemoglobin M, can be treated successfully.

[1]  R. Estabrook,et al.  Evidence for the participation of cytochrome b 5 in hepatic microsomal mixed-function oxidation reactions. , 1971, Archives of biochemistry and biophysics.

[2]  N. Borgese,et al.  A novel point mutation in a 3' splice site of the NADH-cytochrome b5 reductase gene results in immunologically undetectable enzyme and impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with type II hereditary methemoglobinemia. , 1995, American journal of human genetics.

[3]  T. Miale,et al.  Leukocyte diaphorase deficiency in congenital methemoglobinemia: a valuable prognostic indicator. , 1977, Biology of the neonate.

[4]  D. L. Cinti,et al.  Biochemical properties of cytochrome b5-dependent microsomal fatty acid elongation and identification of products. , 1980, The Journal of biological chemistry.

[5]  J. Hoyer,et al.  Hb Chile [beta28(B10)Leu-->Met]: an unstable hemoglobin associated with chronic methemoglobinemia and sulfonamide or methylene blue-induced hemolytic anemia. , 1999, Hemoglobin.

[6]  C. Junien,et al.  Generalised deficiency of cytochrome b5 reductase in congenital methaemoglobinaemia with mental retardation , 1975, Nature.

[7]  K. Titani,et al.  A New Abnormal Fetal Hemoglobin, Hb FM-Osaka (α2γ263His→Tyr) , 1980 .

[8]  P. Laspe,et al.  Molecular basis of recessive congenital methemoglobinemia, types I and II: Exon skipping and three novel missense mutations in the NADH‐cytochrome b5 reductase (diaphorase 1) gene , 2001, Human mutation.

[9]  J. Prchal,et al.  A novel mutation found in the 3' domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. , 1996, Blood.

[10]  S. Iwanaga,et al.  Complete amino acid sequence of NADH-cytochrome b5 reductase purified from human erythrocytes. , 1986, Journal of biochemistry.

[11]  M. Bewley,et al.  The structure of the S127P mutant of cytochrome b5 reductase that causes methemoglobinemia shows the AMP moiety of the flavin occupying the substrate binding site. , 2003, Biochemistry.

[12]  E. Krenzelok,et al.  Environmentally-induced methemoglobinemia in an infant. , 1992, Journal of toxicology. Clinical toxicology.

[13]  K. Inaka,et al.  Crystal structure of NADH-cytochrome b5 reductase from pig liver at 2.4 A resolution. , 1995, Biochemistry.

[14]  Y. Fukumaki,et al.  Two novel mutations in the reduced nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase gene of a patient with generalized type, hereditary methemoglobinemia. , 1996, Blood.

[15]  R. Wanders,et al.  A case of methemoglobinemia type II due to NADH‐cytochrome b5 reductase deficiency: Determination of the molecular basis , 2000, Human mutation.

[16]  S. Shibata,et al.  Hemoglobin M1: Demonstration of a New Abnormal Hemoglobin in Hereditary Nigremia. , 1960 .

[17]  N. Oshino,et al.  A function of cytochrome b5 in fatty acid desaturation by rat liver microsomes. , 1971, Journal of Biochemistry (Tokyo).

[18]  S. Brennan,et al.  HB Auckland [α87(F8)his→ASN]: A new Mutation of the Proximal Histidine Identified by Electrospray Mass Spectrometry , 1997 .

[19]  S. Bradberry Occupational Methaemoglobinaemia , 2003, Toxicological reviews.

[20]  K. Shirabe,et al.  An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. , 1994, The Journal of biological chemistry.

[21]  M. Bewley,et al.  The structure and biochemistry of NADH-dependent cytochrome b5 reductase are now consistent. , 2001, Biochemistry.

[22]  E. Demaeyer,et al.  The prevalence of anaemia in the world. , 1985, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[23]  Yao Wan,et al.  Identification of a novel point mutation (Leu72Pro) in the NADH‐cytochrome b5 reductase gene of a patient with hereditary methaemoglobinaemia type I , 1998, British journal of haematology.

[24]  J. Priest,et al.  Mutant fetal hemoglobin causing cyanosis in a newborn. , 1989, Pediatrics.

[25]  L. Shenkman,et al.  Fatal methemoglobinemia caused by inadvertent contamination of a laxative solution with sodium nitrite. , 1992, Israel journal of medical sciences.

[26]  M. L. Efron,et al.  Chemical studies of several varieties of Hb M. , 1961, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. Borgese,et al.  Enzymatic instability of NADH-cytochrome b5 reductase as a cause of hereditary methemoglobinemia type I (red cell type). , 1992, The Journal of biological chemistry.

[28]  Y. Sakaki,et al.  Serine-proline replacement at residue 127 of NADH-cytochrome b5 reductase causes hereditary methemoglobinemia, generalized type. , 1990, Blood.

[29]  J. Kaplan,et al.  Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II. , 1995, Blood.

[30]  F. Xie,et al.  A novel mutation in the NADH-cytochrome b5 reductase gene of a Chinese patient with recessive congenital methemoglobinemia. , 2000, Blood.

[31]  K. Higasa,et al.  Molecular basis of hereditary methaemoglobinaemia, types I and II: two novel mutations in the NADH‐cytochrome b5 reductase gene , 1998, British journal of haematology.

[32]  M. Eppink,et al.  Seven new mutations in the nicotinamide adenine dinucleotide reduced-cytochrome b(5) reductase gene leading to methemoglobinemia type I. , 2001, Blood.

[33]  E. Harley,et al.  Recessive congenital methaemoglobinaemia type II, a new mutation which causes incorrect splicing in the NADH-cytochrome b5 reductase gene , 1997, Journal of Inherited Metabolic Disease.

[34]  M. Kiese THE BIOCHEMICAL PRODUCTION OF FERRIHEMOGLOBINFORMING DERIVATIVES FROM AROMATIC AMINES, AND MECHANISMS OF FERRHEMOGLOBIN FORMATION , 1966 .

[35]  Q. Gibson The reduction of methaemoglobin in red blood cells and studies on the cause of idiopathic methaemoglobinaemia. , 1948, The Biochemical journal.

[36]  E. Caspi,et al.  Mechanism of C-5 double bond introduction in the biosynthesis of cholesterol by rat liver microsomes. , 1976, The Journal of biological chemistry.

[37]  K. Senger,et al.  Fatal outcome of methemoglobinemia in an infant. , 1987, JAMA.

[38]  G. Irken,et al.  Congenital methaemoglobinaemia Type I in a Turkish infant due to a novel mutation, Pro144Ser, in NADH-cytochrome b5 reductase. , 2004, The hematology journal : the official journal of the European Haematology Association.

[39]  S. Ebbe,et al.  Clinical and laboratory features of two variants of methemoglobin M disease. , 1959, The Journal of laboratory and clinical medicine.

[40]  Y. Sakaki,et al.  Structural role of serine 127 in the NADH-binding site of human NADH-cytochrome b5 reductase. , 1991, The Journal of biological chemistry.

[41]  D E Hultquist,et al.  Catalysis of methaemoglobin reduction by erythrocyte cytochrome B5 and cytochrome B5 reductase. , 1971, Nature: New biology.

[42]  M. McMullin,et al.  Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. , 2002, Blood.

[43]  Y. Sakaki,et al.  The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. , 1989, Gene.

[44]  O BODANSKY,et al.  Methemoglobinemia and methemoglobin-producing compounds. , 1951, Pharmacological reviews.

[45]  A. Tomoda,et al.  Exonic point mutations in NADH-cytochrome B5 reductase genes of homozygotes for hereditary methemoglobinemia, types I and III: putative mechanisms of tissue-dependent enzyme deficiency. , 1991, American journal of human genetics.

[46]  D. Płochocka,et al.  Compound heterozygosity of two missense mutations in the NADH‐cytochrome b5 reductase gene of a Polish patient with type I recessive congenital methaemoglobinaemia , 2003, European journal of haematology.

[47]  P. Board NADH-ferricyanide reductase, a convenient approach to the evaluation of NADH-methaemoglobin reductase in human erythrocytes. , 1981, Clinica chimica acta; international journal of clinical chemistry.